Screening, enrollment, randomization, and follow-up of study participants.
Of 93 subjects screened, 48 met the study criteria and were enrolled and randomly assigned to two treatment groups. Treatment Group 1 comprised 23 participants receiving the thermostable single-vial ID93 + GLA-SE vaccine; Treatment Group 2 comprised 25 participants receiving the non-thermostable two-vial ID93 + GLA-SE vaccine. The safety population represents participants receiving at least one injection. The per-protocol population represents participants that completed the study according to plan.Summary of demographic data and other baseline characteristics in the safety population